Payment overview · 2025
General Payments
$96.49
6 reported records · 6 companies
Healthcare provider profile · identity verified
Eduardo Guzman, MD
Allopathic & Osteopathic Physicians|Family Medicine · PENITAS, TX · NPI 1295780005
Verified facts
What the public records show
CMS Open Payments records show Eduardo Guzman, MD received $96.49 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.34 | 22.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.51 | 20.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.08 | 18.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.08 | 15.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.78 | 14.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.70 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.49 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 948 | 327 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 163 |
| Gabapentin | Gabapentin | 447 | 171 |
| Metformin Hcl | Metformin Hcl | 442 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 366 | 118 |
| Losartan Potassium | Losartan Potassium | 323 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 94 |
| Glipizide | Glipizide | 287 | 92 |
| Jardiance | Empagliflozin | 279 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 277 | 98 |
| Januvia | Sitagliptin Phosphate | 273 | 51 |
| Lisinopril | Lisinopril | 272 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 89 |
| Montelukast Sodium | Montelukast Sodium | 249 | 94 |
| Donepezil Hcl | Donepezil Hcl | 223 | 68 |
| Sertraline Hcl | Sertraline Hcl | 216 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 54 |
| Alendronate Sodium | Alendronate Sodium | 186 | 59 |
| Omeprazole | Omeprazole | 186 | 75 |
| Famotidine | Famotidine | 181 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 172 | 54 |
| Furosemide | Furosemide | 166 | 69 |
| Trazodone Hcl | Trazodone Hcl | 166 | 59 |
| Trulicity | Dulaglutide | 165 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 159 | 123 |
| Ozempic | Semaglutide | 158 | 36 |
| Linzess | Linaclotide | 157 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 157 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 156 | 59 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 150 | 115 |
| Prednisone | Prednisone | 149 | 113 |
| Ezetimibe | Ezetimibe | 139 | 52 |
| Alprazolam | Alprazolam | 135 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 132 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 44 |
| Celecoxib | Celecoxib | 127 | 71 |
| Tramadol Hcl | Tramadol Hcl | 126 | 28 |
| Myrbetriq | Mirabegron | 125 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 42 |
| Xarelto | Rivaroxaban | 101 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 99 | 37 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 98 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 33 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 96 | 24 |
| Azithromycin | Azithromycin | 95 | 77 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 93 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 36 |
| Vascepa | Icosapent Ethyl | 87 | 27 |
| Carvedilol | Carvedilol | 82 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 76 | 61 |
| Finasteride | Finasteride | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 33 |
| Meclizine Hcl | Meclizine Hcl | 70 | 41 |
| Allopurinol | Allopurinol | 69 | 19 |
| Farxiga | Dapagliflozin Propanediol | 69 | 17 |
| Ibuprofen | Ibuprofen | 66 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 17 |
| Naproxen | Naproxen | 66 | 34 |
| Synjardy | Empagliflozin/Metformin Hcl | 66 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 60 | 28 |
| Memantine Hcl | Memantine Hcl | 60 | 25 |
| Cefdinir | Cefdinir | 59 | 53 |
| Simvastatin | Simvastatin | 59 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 18 |
| Eliquis | Apixaban | 56 | 13 |
| Mupirocin | Mupirocin | 55 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 38 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 17 |
| Desloratadine | Desloratadine | 52 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 51 | 16 |
| Meloxicam | Meloxicam | 50 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 44 |
| Cephalexin | Cephalexin | 47 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 18 |
| Tradjenta | Linagliptin | 45 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 17 |
| Entresto | Sacubitril/Valsartan | 42 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | 19 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 19 |
| Sucralfate | Sucralfate | 36 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Enalapril Maleate | Enalapril Maleate | 33 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 33 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 14 |
| Hydrocortisone | Hydrocortisone | 32 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 28 |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Cilostazol | Cilostazol | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 13 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Ciclopirox | Ciclopirox | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 21 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 19 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 11 |
| Baclofen | Baclofen | 25 | 11 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metolazone | Metolazone | 22 | 12 |
| Valacyclovir | Valacyclovir Hcl | 22 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | 14 |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terconazole | Terconazole | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $96.49 · 6 records | PFIZER INC. | AIRSUPRA, ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, VOQUEZNA, Wegovy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error